Member Profile

Founded in 2001, TaiGen Biotechnology Co., Ltd. is a research-based and market-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases. TaiGen has a wholly-owned Beijing subsidiary with proven capacities to conduct clinical trials and related registrations. TaiGen Biotechnology became a publicly listed company in Taipei Exchange (Ticker 4157.TWO) in January 2014.

TaiGen’s pipeline includes in-house discovered and developed new chemical entities: TG-1000, a novel antiviral for influenza, received China and US IND authorization in 2020. TaiGen successfully completed the unblinding of TG-1000 phase III clinical trial and filed New Drug Application (NDA) in mainland China in 2024. Taigexyn® capsule, a novel antibiotic, is the first NCEs developed by a Taiwanese company that received market approval and launched in mainland China and Taiwan. Taigexyn® intravenous formulation is also marketed in Taiwan and mainland China in 2020 & 2021 respectively, Taigexyn® IV becomes eligible for reimbursement in March as it passed the National Health Insurance Administration’s review and assessment on Feb 14 in Taiwan. Taigexyn is also granted three nationals prizes, SNQ, National Bio & Medicine Care Quality Award and National Innovation Award for Sustainability excellence. Taigexyn® is partnered in 35 countries worldwide. Licensed partners include GPCR for South Korea; R-Pharm for the Russian Federation and the Commonwealth of Independent States; Productos Científicos for Latin America; and Holding Distribution for distribution in Taiwan.